FDA approves ProStrakan's Rectiv for pain associated with anal fissures

ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for Rectiv™ (nitroglycerin) Ointment 0.4 % for the treatment of moderate to severe pain associated with chronic anal fissures.  Rectiv will be the only FDA approved prescription product for patients with this condition.

"The pain associated with anal fissures can be unrelenting and debilitating. Prompt initiation of treatment by primary care practitioners, gynecologists, gastroenterologists and surgeons alike is critical to a patient's wellbeing," said Scott Berry MD, FACS, colorectal surgeon and the principal investigator on one of Rectiv's clinical trials.

"Now we have an effective and easy-to-use topical ointment which allows grateful patients to resume their daily lives."

Anal fissures are fairly common, with approximately 700,000 people in the U.S. receiving a diagnosis or treatment for an episode each year.   An anal fissure is a small tear in the skin that lines the anus, and can occur in a number of ways such as passing large or hard stools, straining during a bowel movement, or following an episode of diarrhea. When an anal fissure occurs, it typically causes severe pain and bleeding with bowel movements. Chronic anal fissure has been shown to impact significantly on patients' quality of life.  An episode can take six to eight weeks to heal; and if healing does not occur then surgery may be required.

Peter Allen, Chairman of ProStrakan, said:

"The market in the U.S. for a prescription medicine to treat chronic anal fissure pain is significant and, having successfully marketed this product in Europe for some years, we are pleased that it will now be made available to patients in the U.S."

"We will now evaluate the most efficient way of bringing this product to market and making it available as widely as is necessary."

ProStrakan expects Rectiv to be available in the U.S. in the first quarter of 2012.  Marketed under the name Rectogesic®, the product is already approved in the EU and marketed by ProStrakan in all major European countries, where sales grew by 15% in 2010 to $14.4 million (9.3 million Pounds Sterling).  The product has also been out-licensed outside Europe by ProStrakan to commercial partners in 34 countries worldwide.

Source:

ProStrakan Group plc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Medical staff with a history of allergy suffered adverse reactions to BNT162b2 COVID-19 vaccine